Tiny skin study dives deep into psoriasis treatment secrets
NCT ID NCT07244744
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the drug tildrakizumab affects immune cells in the skin of 3 adults with moderate to severe plaque psoriasis. Researchers take small skin samples before and after treatment to see changes in certain cell types. The goal is to learn why the drug works well for some people and how long its effects last.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CCIM, Institut für Entzündungsmedizin UKSH Lübeck
Lübeck, <Keine Auswahl>, 23562, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?
- Can a switch to guselkumab clear stubborn psoriasis?
- Can a new biologic clear stubborn psoriasis?
- Diet and exercise may tame psoriasis in kids — a trial puts it to the test
- Ancient herbal mix put to the test against psoriasis